ClinicalTrials.gg
CompletedNCT06358365Updated May 3, 2024

Enhancing Fluid Transfer Through the Skin, by Increased Sweat Rate, on Hemodialysis Patients

An interventional study of The AquaPass System in Acute Kidney Failure and Chronic Kidney Diseases, sponsored by AquaPass Medical Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Acute Kidney Injury with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Israel.

Started
2023
the only one that year
No phase
4 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
AquaPass Medical Ltd.

Among the 13 studies in Acute Kidney Injury with a site in Israel, this one is the only one that started in 2023, is one of 4 with no phase, and was the 10th registered.

Acute Kidney Injury

1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 13 studies in Acute Kidney Injury with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute Kidney Injury with a site in Israel, or all of them as a file.
02

Study summary

To demonstrate safety and performance of AquaPass System for improving fluid balance in hemo-dialysis patients, by increasing fluid loss via the skin.

Read the detailed description

This study requires several investigational tests, exams, and data collection procedures to be performed by the participants. These procedures are listed in abbreviated format in the Schedule of Assessments/Activities table. The final eligibility of the trial will be confirmed after a 2-hour acclimatization session. The trial-specific procedures must not be performed until the participant has signed a written informed consent form, which has been approved by the site's Institutional Review Board.

The investigator or designee, who is trained in the clinical investigation plan, will explain the nature and scope of the trial to the participant. They will also discuss the potential risks and benefits of participation and answer any questions the participant may have. If the participant agrees to participate, they must sign the informed consent form. The investigator/designee must also sign the form before the participant can be enrolled in the trial. Any additional persons required by the site's Institutional Review Board to sign the informed consent form must also comply.

Each participant's study duration will be approximately 8 weeks. The study duration will be identical for all participants, as follows:

Screening Period: This period will last up to 7 days, during which time the participant's eligibility for the trial will be determined.

Observation Period: This period will last 3 weeks, during which the participant will come to the medical study center for weekly assessments.

Procedure Period: This period will last 4 weeks, during which time the participant will undergo 2-3 procedures with the AquaPass device each week. These procedures will be in addition to their regular hemodialysis treatment. The participant will undergo 2 procedures during the weekend, and each procedure will last 3-8 hours.

Follow-Up: This period will last 7(±1) days from the last procedure. During this period, the participant's health status will be monitored.

In summary, the study requires participants to undergo several investigational tests, exams, and data collection procedures. The study duration for each participant will be approximately 8 weeks, during which time they will undergo a screening period, observation period, procedure period, and follow-up period. All participants must provide written informed consent before any trial-specific procedures can be performed.

03

Conditions studied

  • Acute Kidney Failure
  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18
  2. Undergoing regular hemodialysis for ≥3 months
  3. Subject is capable of meeting study requirements including follow-up visit
  4. Subject completed 2-hour acclimatization session

Exclusion criteria

Exclusion Criteria:

  1. Subject is enrolled to another clinical investigation that might interfere with this study
  2. Subject does not have any known skin problems (open or uncovered wounds, ulcers)
  3. Subject is pregnant or planning to become pregnant within the study period, or lactating mothers
  4. Scheduled living donor renal transplant during study participation
  5. Has resting pre-dialysis systolic blood pressure \<100mmHg
  6. Limb/s amputation
  7. Hyperkalemia > 6meq/d"l
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    adult patients undergoing regular hemodialysis

    This study will be a crossover study with one center and an open label design. Patients who sign the informed consent form and meet the inclusion and exclusion criteria will undergo a 2-hour acclimatization period to verify their ability to adhere to the AquaPass procedure. Once enrolled, patients will undergo a 3-week observation period where they will continue with their regular hemodialysis treatment with no changes. Study endpoint parameters will be assessed during this observation period and used as a control group. After the observation period, patients will undergo the AquaPass procedure 2-3 times a week for 4 weeks. Study assessments will be conducted at the beginning of each week during the patient's dialysis session.

    Device: The AquaPass System

Interventions

  • DeviceThe AquaPass System

    The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.

06

What researchers measure

Primary outcomes

  1. Differences in weight gain over the long interdialytic period

    weight at the end of the last Hemodialysis session before AquaPass therapy subtracted from the weight in the morning of the first Hemodialysis session of the week after AquaPass therapy.

    Time frame: Up to 50 days

  2. Device related Adverse Events

    Safety evaluation of device-related adverse effects

    Time frame: Up to 60 Days

Secondary outcomes

  1. Changes in NT-proBNP

    Changes in biomarkers of congestion

    Time frame: Up to 50 days

  2. Changes in Blood Urea Nitrogen

    Changes in Blood Urea Nitrogen levels

    Time frame: Up to 50 days

  3. Effect on Quality of Life

    change in the quality of life measured by the Kansas City Cardiomyopathy Questionnaire. In this questionnaire the minimum score is '0' and the maximum is '100', and higher scores represent a better outcome for the patient.

    Time frame: up to 50 days

  4. Affect on Ultrafiltration Rates after the long inter dialytic gap

    Evaluation of the changes in ultrafiltration rates between the control phase and the Aquapass phase in the first dialysis session after the long interdialytic period

    Time frame: up to 28 days

07

Study locations

1 site
  • Nazareth Hospital EMMS
    Nazareth, Al Wadi Al Jawani 1611 16100, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2023, 7 months.

Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Apr 10, 2024
StartActual
Mar 29, 2023
Primary completionActual
Nov 2, 2023
CompletionActual
Nov 7, 2023
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06358365
Lead sponsor
AquaPass Medical Ltd.
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Mar 29, 2023
Primary completion
Nov 2, 2023
Completion
Nov 7, 2023
Last update
May 3, 2024

Study contacts

Zaher Armaly, MD
principal investigator · CEO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion